

Pedro Valdivielso

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9316377/publications.pdf>

Version: 2024-02-01

96
papers

1,929
citations

257101

24
h-index

288905

40
g-index

113
all docs

113
docs citations

113
times ranked

2514
citing authors

#	ARTICLE	IF	CITATIONS
1	Situación en 2020 de los requerimientos para la utilización de inhibidores de PCSK9 en España: resultados de una encuesta nacional. <i>Clínica E Investigaci3n En Arteriosclerosis</i> , 2022, 34, 10-18.	0.4	4
2	Postprandial Hyperlipidemia: Association with Inflammation and Subclinical Atherosclerosis in Patients with Rheumatoid Arthritis. <i>Biomedicines</i> , 2022, 10, 133.	1.4	6
3	EstÁndares SEA 2022 para el control global del riesgo cardiovascular. <i>Clínica E Investigaci3n En Arteriosclerosis</i> , 2022, 34, 130-179.	0.4	11
4	Situation in 2020 of the requirements for the use of PCSK9 inhibitors in Spain: Results of a national survey. <i>Clínica E Investigaci3n En Arteriosclerosis (English Edition)</i> , 2022, 34, 10-18.	0.1	0
5	Protocolo del observatorio de las dislipemias: Tratamiento de la hipercolesterolemia en España, contexto e identificaci3n de medidas de mejora en prÁctica clÁnica habitual. <i>Clínica E Investigaci3n En Arteriosclerosis</i> , 2022, 34, 253-260.	0.4	1
6	Mitochondrial Homeostasis in Obesity-related Hypertriglyceridemia. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2022, 107, 2203-2215.	1.8	3
7	El laboratorio clÁnico en la prevenci3n cardiovascular: el caso de los mapas cloroplÁcticos. <i>REC: CardioClinics</i> , 2022, 57, 234-234.	0.1	0
8	Prediction of fatal and non-fatal cardiovascular events in young and middle-aged healthy workers: The IberScore model. <i>European Journal of Preventive Cardiology</i> , 2021, 28, 177-186.	0.8	12
9	Cumulative inflammatory burden and obesity as determinants of insulin resistance in patients with established rheumatoid arthritis: cross-sectional study. <i>BMJ Open</i> , 2021, 11, e044749.	0.8	9
10	Role of patients associations in connective tissue calcifying diseases: a position statement from EuroSoftCalc.Net group. <i>Orphanet Journal of Rare Diseases</i> , 2021, 16, 71.	1.2	0
11	Physicochemical Properties of Lipoproteins Assessed by Nuclear Magnetic Resonance as a Predictor of Premature Cardiovascular Disease. PRESARV-SEA Study. <i>Journal of Clinical Medicine</i> , 2021, 10, 1379.	1.0	2
12	Nuevos tratamientos en la dislipemia. <i>Clínica E Investigaci3n En Arteriosclerosis</i> , 2021, 33, 1-2.	0.4	0
13	Tratamiento de la quilomicronemia. <i>Clínica E Investigaci3n En Arteriosclerosis</i> , 2021, 33, 75-79.	0.4	2
14	Implantaci3n de un programa de cribado bioquÁmico y gen3tico de hipercolesterolemia familiar. Colaboraci3n entre el laboratorio clÁnico y las unidades de lÁpidos: dise±o del Proyecto ARIAN. <i>Clínica E Investigaci3n En Arteriosclerosis</i> , 2021, 33, 289-295.	0.4	2
15	Cutaneous and Vascular Deposits of 18F-NaF by PET/CT in the Follow-Up of Patients with Pseudoxanthoma Elasticum. <i>Journal of Clinical Medicine</i> , 2021, 10, 2588.	1.0	3
16	Prevalence of familial hypercholesterolemia phenotype and ten-year risk of cardiovascular events in a working population in primary prevention: The ICARIA study. <i>Atherosclerosis</i> , 2021, 338, 39-45.	0.4	2
17	Genetic variants in the LPL and GPIHBP1 genes, in patients with severe hypertriglyceridaemia, detected with high resolution melting analysis. <i>Clinica Chimica Acta</i> , 2020, 500, 163-171.	0.5	8
18	Overall Mortality and LDL Cholesterol Reduction in Secondary Prevention Trials of Cardiovascular Disease. <i>American Journal of Cardiovascular Drugs</i> , 2020, 20, 325-332.	1.0	0

#	ARTICLE	IF	CITATIONS
19	Clinical and genetic differences between heterozygous familial hypercholesterolemia patients with and without type 2 diabetes. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2020, 73, 718-724.	0.4	6
20	Consensus document of an expert group from the Spanish Society of Arteriosclerosis (SEA) on the clinical use of nuclear magnetic resonance to assess lipoprotein metabolism (Liposcale®). <i>Clínica E Investigaci3n En Arteriosclerosis (English Edition)</i> , 2020, 32, 219-229.	0.1	6
21	Documento de consenso de un grupo de expertos de la Sociedad Espa±ola de Arteriosclerosis (SEA) sobre el uso clínico de la resonancia magnética nuclear en el estudio del metabolismo lipoproteico (Liposcale). <i>Clínica E Investigaci3n En Arteriosclerosis</i> , 2020, 32, 219-229.	0.4	9
22	Postprandial Apolipoprotein B48 is Associated with Subclinical Atherosclerosis in Patients with Rheumatoid Arthritis. <i>Journal of Clinical Medicine</i> , 2020, 9, 2483.	1.0	11
23	Skin and Arterial Wall Deposits of 18F-NaF and Severity of Disease in Patients with Pseudoxanthoma Elasticum. <i>Journal of Clinical Medicine</i> , 2020, 9, 1393.	1.0	7
24	Evaluation of the chylomicronâ€TTC to VLDLâ€TTC ratio for type I hyperlipoproteinemia diagnostic. <i>European Journal of Clinical Investigation</i> , 2020, 50, e13345.	1.7	16
25	Subclinical Arteriosclerosis is Associated with Common Vascular Risk Factors in Long-Term Survivors of Testicular Cancer. <i>Journal of Clinical Medicine</i> , 2020, 9, 971.	1.0	0
26	Relationship Between Mitochondrial Structure and Bioenergetics in Pseudoxanthoma elasticum Dermal Fibroblasts. <i>Frontiers in Cell and Developmental Biology</i> , 2020, 8, 610266.	1.8	12
27	COVID-19 and Sick Leave: An Analysis of the Ibermutua Cohort of Over 1,651,305 Spanish Workers in the First Trimester of 2020. <i>Frontiers in Public Health</i> , 2020, 8, 580546.	1.3	26
28	Criterios de derivaci3n para pacientes a las unidades de lÃpidos de la Sociedad Espa±ola de Arteriosclerosis. <i>Clínica E Investigaci3n En Arteriosclerosis</i> , 2019, 31, 26-30.	0.4	7
29	EstÃndares SEA 2019 para el control global del riesgo cardiovascular. <i>Clínica E Investigaci3n En Arteriosclerosis</i> , 2019, 31, 1-43.	0.4	8
30	Indicaciones de los inhibidores de PCSK9 en la prÃctica clínica. Recomendaciones de la Sociedad Espa±ola de Arteriosclerosis (SEA), 2019. <i>Clínica E Investigaci3n En Arteriosclerosis</i> , 2019, 31, 128-139.	0.4	28
31	Toward a new clinical classification of patients with familial hypercholesterolemia: One perspective from Spain. <i>Atherosclerosis</i> , 2019, 287, 89-92.	0.4	29
32	Criteria for referring patients to Spanish Atherosclerosis Society lipid units. <i>Clínica E Investigaci3n En Arteriosclerosis (English Edition)</i> , 2019, 31, 26-30.	0.1	2
33	Plasma inorganic pyrophosphate and alkaline phosphatase in patients with pseudoxanthoma elasticum. <i>Annals of Translational Medicine</i> , 2019, 7, 798-798.	0.7	26
34	Fractional excretion of phosphorus and vascular calcification in stage 3 chronic kidney disease. <i>Journal of Investigative Medicine</i> , 2019, 67, 674-680.	0.7	8
35	Internal Carotid Artery Hypoplasia: A New Clinical Feature in Pseudoxanthoma Elasticum. <i>Journal of Stroke</i> , 2019, 21, 108-111.	1.4	13
36	Evaluaci3n de la carga ateroescler3tica en hipertensos con prediabetes. <i>Clínica E Investigaci3n En Arteriosclerosis</i> , 2019, 31, 160-165.	0.4	1

#	ARTICLE	IF	CITATIONS
37	Evidence for increased chylomicron remnants in rheumatoid arthritis. <i>European Journal of Clinical Investigation</i> , 2018, 48, e12873.	1.7	8
38	Documento de recomendaciones de la SEA 2018. El estilo de vida en la prevención cardiovascular. <i>Clínica E Investigación En Arteriosclerosis</i> , 2018, 30, 280-310.	0.4	20
39	COSMIC project: consensus on the objectives of the metabolic syndrome in clinic. <i>Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy</i> , 2018, Volume 11, 683-697.	1.1	19
40	High risk of subclinical atherosclerosis in COPD exacerbator phenotype. <i>Respiratory Medicine</i> , 2018, 141, 165-171.	1.3	8
41	Molecular basis of the familial chylomicronemia syndrome in patients from the National Dyslipidemia Registry of the Spanish Atherosclerosis Society. <i>Journal of Clinical Lipidology</i> , 2018, 12, 1482-1492.e3.	0.6	22
42	Endogenous Calcification Inhibitors in the Prevention of Vascular Calcification: A Consensus Statement From the COST Action EuroSoftCalcNet. <i>Frontiers in Cardiovascular Medicine</i> , 2018, 5, 196.	1.1	82
43	How many familial hypercholesterolemia patients are eligible for PCSK9 inhibition?. <i>Atherosclerosis</i> , 2017, 262, 107-112.	0.4	22
44	Registro Nacional de Dislipemias de la Sociedad Española de Arteriosclerosis: situación actual. <i>Clínica E Investigación En Arteriosclerosis</i> , 2017, 29, 248-253.	0.4	20
45	Brain Functional Connectivity Is Modified by a Hypocaloric Mediterranean Diet and Physical Activity in Obese Women. <i>Nutrients</i> , 2017, 9, 685.	1.7	14
46	Insulin resistance and levels of adipokines in patients with untreated early rheumatoid arthritis. <i>Clinical Rheumatology</i> , 2016, 35, 43-53.	1.0	29
47	Novel mutations in the GPIHBP1 gene identified in 2 patients with recurrent acute pancreatitis. <i>Journal of Clinical Lipidology</i> , 2016, 10, 92-100.e1.	0.6	27
48	In vivo evidence for chylomicrons as mediators of postprandial inflammation. <i>Atherosclerosis</i> , 2015, 243, 540-545.	0.4	18
49	Factors influencing return-to-work after cerebrovascular disease: the importance of previous cardiovascular risk. <i>European Journal of Preventive Cardiology</i> , 2015, 22, 1220-1227.	0.8	13
50	Predictive factors of achieving therapeutic goals of hypertriglyceridemia. <i>Current Medical Research and Opinion</i> , 2014, 30, 19-26.	0.9	11
51	Therapeutic inertia in hypercholesterolaemia is associated with ischaemic events in primary care patients. A case-control study. <i>International Journal of Clinical Practice</i> , 2014, 68, 1001-1009.	0.8	7
52	Current knowledge of hypertriglyceridemic pancreatitis. <i>European Journal of Internal Medicine</i> , 2014, 25, 689-694.	1.0	311
53	Clinical decisions in patients with diabetes and other cardiovascular risk factors. A statement of the Spanish Society of Internal Medicine. <i>Revista Clinica Espanola</i> , 2014, 214, 209-215.	0.2	4
54	Plasmapheresis as treatment for hyperlipidemic pancreatitis. <i>European Journal of Internal Medicine</i> , 2014, 25, 160-163.	1.0	54

#	ARTICLE	IF	CITATIONS
55	Prevalence of atherogenic dyslipidemia: Association with risk factors and cardiovascular risk in Spanish working population. "ICARIA" study. <i>Atherosclerosis</i> , 2014, 235, 562-569.	0.4	26
56	Peripheral arterial disease, type 2 diabetes and postprandial lipidaemia: Is there a link?. <i>World Journal of Diabetes</i> , 2014, 5, 577.	1.3	18
57	Fasting apolipoprotein B48 is a marker for peripheral arterial disease in type 2 diabetes. <i>Acta Diabetologica</i> , 2013, 50, 383-389.	1.2	12
58	Cardiovascular disease and hypertriglyceridemia: a report from the hypertriglyceridemia registry of the Spanish Atherosclerosis Society. <i>Clinical Lipidology</i> , 2013, 8, 525-532.	0.4	4
59	Comment on ESH position paper. <i>Journal of Hypertension</i> , 2012, 30, 2441-2442.	0.3	3
60	Triglyceride levels and apolipoprotein E polymorphism in patients with acute pancreatitis. <i>Hepatobiliary and Pancreatic Diseases International</i> , 2012, 11, 96-101.	0.6	35
61	Grosor Antima-media carotÍdeo: de la investigaci3n a la clÍnica. <i>ClÍnica E Investigaci3n En Arteriosclerosis</i> , 2012, 24, 202-203.	0.4	0
62	Exploring the value of apoB48 as a marker for atherosclerosis in clinical practice. <i>European Journal of Clinical Investigation</i> , 2012, 42, 702-708.	1.7	35
63	¿QuÍ aporta la universidad a la investigaci3n de los hospitales?. <i>CardiCore</i> , 2011, 46, 127-130.	0.0	2
64	Análisis de la influencia de polimorfismos en APOE, APOA5, LPL, LIPC y CETP sobre los niveles de triglicéridos en poblaci3n laboral malagueña. <i>ClÍnica E Investigaci3n En Arteriosclerosis</i> , 2011, 23, 62-71.	0.4	1
65	Prevalence of metabolic syndrome and cardiovascular disease in a hypertriglyceridemic population. <i>European Journal of Internal Medicine</i> , 2011, 22, 177-181.	1.0	28
66	Riesgo vascular, diabetes e Índice tobillo-brazo. <i>Revista Espanola De Cardiologia</i> , 2011, 64, 729.	0.6	0
67	Vascular Risk, Diabetes and the Ankle-Brachial Index. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2011, 64, 729.	0.4	0
68	Effect of apolipoprotein C3 and apolipoprotein A1 polymorphisms on postprandial response to a fat overload in metabolic syndrome patients. <i>Clinical Biochemistry</i> , 2010, 43, 1300-1304.	0.8	10
69	Additive effects of LPL, APOA5 and APOE variant combinations on triglyceride levels and hypertriglyceridemia: results of the ICARIA genetic sub-study. <i>BMC Medical Genetics</i> , 2010, 11, 66.	2.1	55
70	Higher Red Blood Cell Distribution Width Is Associated With the Metabolic Syndrome. <i>Diabetes Care</i> , 2010, 33, e40-e40.	4.3	70
71	Postprandial apolipoprotein B48 is associated with asymptomatic peripheral arterial disease: A study in patients with type 2 diabetes and controls. <i>Clinica Chimica Acta</i> , 2010, 411, 433-437.	0.5	26
72	Lipoprotein lipase activity and mass, apolipoprotein C-II mass and polymorphisms of apolipoproteins E and A5 in subjects with prior acute hypertriglyceridaemic pancreatitis. <i>BMC Gastroenterology</i> , 2009, 9, 46.	0.8	26

#	ARTICLE	IF	CITATIONS
73	Omega 3 fatty acids induce a marked reduction of apolipoprotein B48 when added to fluvastatin in patients with type 2 diabetes and mixed hyperlipidemia: a preliminary report. Cardiovascular Diabetology, 2009, 8, 1.	2.7	55
74	Thigh and buttock exertional pain for the diagnosis of peripheral arterial disease. European Journal of Internal Medicine, 2009, 20, 429-434.	1.0	5
75	Association of moderate and severe hypertriglyceridemia with obesity, diabetes mellitus and vascular disease in the Spanish working population: Results of the ICARIA study. Atherosclerosis, 2009, 207, 573-578.	0.4	40
76	Association of the -250G/A promoter polymorphism of the hepatic lipase gene with the risk of peripheral arterial disease in type 2 diabetic patients. Journal of Diabetes and Its Complications, 2008, 22, 273-277.	1.2	13
77	Sub-clinical vascular disease in type 2 diabetic subjects: Relationship with chronic complications of diabetes and the presence of cardiovascular disease risk factors. European Journal of Internal Medicine, 2008, 19, 255-260.	1.0	26
78	Parameters of oxidative stress are present in the circulation of PXE patients. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2008, 1782, 474-481.	1.8	46
79	HYPERTRIGLYCERIDEMIA, CARDIOVASCULAR RISK FACTORS, AND GLOBAL CARDIOVASCULAR RISK IN THE SPANISH WORKING POPULATION. ICARIA STUDY GROUP. Atherosclerosis Supplements, 2008, 9, 17.	1.2	0
80	ASSOCIATION OF APO A5 VARIANTS -1131T/C AND S19W WITH HYPERTRIGLYCERIDEMIA IN A MEDITERRANEAN SPANISH WORKING POPULATION. Atherosclerosis Supplements, 2008, 9, 111-112.	1.2	0
81	Polimorfismo ϵ -250G/A de LIPC y su asociaci3n con la enfermedad arterial perif3rica en pacientes con diabetes tipo 2. Cl3nica E Investigaci3n En Arteriosclerosis, 2008, 20, 22-27.	0.4	0
82	Respuesta posprandial de la apolipoprote3na B-48 y del perfil lip3dico en pacientes con diabetes mellitus tipo 2. Cl3nica E Investigaci3n En Arteriosclerosis, 2008, 20, 145-150.	0.4	0
83	Peripheral Arterial Disease in HIV Patients Older than 50 Years of Age. AIDS Research and Human Retroviruses, 2008, 24, 1043-1046.	0.5	39
84	Occupation-Related Differences in the Prevalence of Metabolic Syndrome. Diabetes Care, 2008, 31, 1884-1885.	4.3	77
85	Smoking and postprandial triglycerides are associated with vascular disease in patients with type 2 diabetes. Atherosclerosis, 2007, 194, 391-396.	0.4	19
86	Registro de hipertrigliceridemias de la Sociedad Espa3ola de Arteriosclerosis. Cl3nica E Investigaci3n En Arteriosclerosis, 2007, 19, 303-307.	0.4	6
87	W08-P-034 Lack of association between central obesity and postprandial triglycerides. Atherosclerosis Supplements, 2005, 6, 38.	1.2	0
88	Atorvastatin in dyslipidaemia of the nephrotic syndrome. Nephrology, 2003, 8, 61-64.	0.7	15
89	Short-Term Lipid Changes Associated With Highly Active Antiretroviral Therapy in Naive HIV-Infected Patients. Journal of Acquired Immune Deficiency Syndromes (1999), 2003, 34, 249-251.	0.9	13
90	Human immunodeficiency virus infection and systemic lupus erythematosus. An unusual case and a review of the literature. Lupus, 2002, 11, 60-63.	0.8	50

#	ARTICLE	IF	CITATIONS
91	Efficacy and Safety of Fenofibrate for the Treatment of Hypertriglyceridemia Associated With Antiretroviral Therapy. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2002, 31, 251-253.	0.9	23
92	Efficacy and Safety of Atorvastatin in the Treatment of Hypercholesterolemia Associated With Antiretroviral Therapy. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2002, 30, 536-537.	0.9	35
93	2.P.291 Effects of tibolone on lipoproteins. <i>Atherosclerosis</i> , 1997, 134, 177.	0.4	1
94	Lipids and lipoproteins in cord blood: analyses of a Hispanic and Arab population. <i>Acta Paediatrica, International Journal of Paediatrics</i> , 1992, 81, 439-440.	0.7	7
95	Localized rheumatoid vasculitis presenting as acute alithiasic cholecystitis. <i>American Journal of Medicine</i> , 1991, 91, 90-92.	0.6	16
96	Apolipoprotein distribution in plasma HDL subfractions in alcohol consumers. <i>Drug and Alcohol Dependence</i> , 1990, 26, 161-168.	1.6	5